We are a ‘virtual’ institute. Our community is based at Dutch universities, research institutes and hospitals.

In 2018, we welcomed three new partner institutes, bringing the total number to twelve.

Our founding scientists laid the foundations and worked tirelessly to make Oncode Institute a reality.

With gratitude to our founding scientists, a new generation took over. Geert Kops was appointed as our new Scientific Director, supported by a diverse Research Management Committee.

Oncode Institute brings together brilliant minds in molecular cancer research throughout the Netherlands.

During the course of 2018 we grew from 43 to 62 Oncode Investigators, bringing the total number of Oncode researchers to more than 800.

To stimulate curiosity-driven research, our 62 Oncode Investigators receive base funding to stimulate high-risk, high-gain projects.

“Oncode funding was used to support the development of synthetic dendritic cells and synthetic immune niches. These were two very high-risk projects, because the proposed structures have never been tested in vivo” says Oncode Investigator Carl Figdor.

We recruited a diverse team of Business Development experts to help translate fundamental science into benefits for patients and society.

Based on the single-cell sequencing capabilities and expertise of the Hubrecht Institute, one of the first signs of success was the launch of our first spin-off company – Single Cell Discoveries.

We streamline all our efforts through a unifying research strategy, with six scientific themes.

To stimulate collaboration and bring our researchers together, we organized our first Annual Conference and three Scientific Theme meetings.

Medical innovations are only useful when access for patients is guaranteed. With our Affordable Health Care programme we aim to contribute to a sustainable future for cancer care.

Together with ZonMw we set up a funding call to support projects looking into precision diagnostics and drug repurposing.

Because impacting lives means efficiently translating fundamental findings to the clinic, Oncode invests heavily in collaborating with clinicians.

With dedicated funding and expert support, we launched our clinical Proof of Concept programme and selected six translational projects for funding.

Oncode aims to bring the world of fundamental science closer to the everyday reality of patients.

With the addition of patient representatives to both our Clinical Advisory Board and Supervisory Board, we have strengthened the ‘voice of the patient’ in our institute.